Newsfeeds - Spark Newswire

1 minute read

Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis

Today, 10:05 PM

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) announced topline results from the ARRECTOR Pivotal Phase 3 trial of roflumilast foam 0.3% for treating adults…

ARQT

1 minute read

Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp And Body Psoriasis; Study Met Both Co-Primary Endpoints And All Secondary Endpoints

By Bill Haddad

Today, 10:05 PM

Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1%

ARQT

1 minute read

JonesTrading Assumes Arcutis Biotherapeutics at Buy, Announces Price Target of $54

By Benzinga Newsdesk

Today, 10:05 PM

JonesTrading analyst Sean Kim assumes Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces Price Target of $54.

ARQT

3 minute read

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 10:05 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

1 minute read

Arcutis Biotherapeutics Presents Data From STRATUM Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Seborrheic Dermatitis Presented At European Academy Of Dermatology And Venereology Congress

By Bill Haddad

Today, 10:05 PM

Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle

ARQT

3 minute read

M&A
News

Arcutis Announces Acquisition of Ducentis BioTherapeutics For $16M

By Michael Horton

Today, 10:05 PM

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced it has entered into an agreement

ARQT